Mucopolysaccharidosis type II, Iduronate sulfatase deficiency
The U.S. Food and Drug Administration has approved the first treatment for Hunter syndrome. The medicine, called idursulfase (Elaprase), is given through a vein (intravenously). Talk to your doctor for more information.
Bone marrow transplant has been tried for the early-onset form with variable results.
Individual problems should be addressed separately.
Life expectancy for the early-onset (severe) form is 10 - 20 years. Life expectancy for the late-onset (mild) form is 20 - 60 years.
Call your health care provider if you or your child manifest a group of these symptoms, or if you know you are a genetic carrier and are considering having children.
Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006 Aug;8(8):465-73.